AU2015274554B9 - N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide hydrochloride salts - Google Patents

N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide hydrochloride salts Download PDF

Info

Publication number
AU2015274554B9
AU2015274554B9 AU2015274554A AU2015274554A AU2015274554B9 AU 2015274554 B9 AU2015274554 B9 AU 2015274554B9 AU 2015274554 A AU2015274554 A AU 2015274554A AU 2015274554 A AU2015274554 A AU 2015274554A AU 2015274554 B9 AU2015274554 B9 AU 2015274554B9
Authority
AU
Australia
Prior art keywords
cyt
pyrimidin
cyanomethyl
morpholinophenylamino
benzamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
AU2015274554A
Other languages
English (en)
Other versions
AU2015274554B2 (en
AU2015274554A1 (en
Inventor
Brandon H. Brown
Ernest A. Carra
Jeffrey N. Hemenway
Henry Morrison
Troy Reynolds
Bing Shi
Dimitrios Stefanidis
Fang Wang
Matthew Robert Warr
James Andrew Whitney
Yan Xin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline LLC
Original Assignee
GlaxoSmithKline LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53674249&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2015274554(B9) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by GlaxoSmithKline LLC filed Critical GlaxoSmithKline LLC
Publication of AU2015274554A1 publication Critical patent/AU2015274554A1/en
Publication of AU2015274554B2 publication Critical patent/AU2015274554B2/en
Application granted granted Critical
Publication of AU2015274554B9 publication Critical patent/AU2015274554B9/en
Assigned to SIERRA ONCOLOGY, INC. reassignment SIERRA ONCOLOGY, INC. Request for Assignment Assignors: GILEAD SCIENCES, INC.
Assigned to GLAXOSMITHKLINE LLC reassignment GLAXOSMITHKLINE LLC Request for Assignment Assignors: SIERRA ONCOLOGY, INC.
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2015274554A 2014-06-12 2015-06-11 N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide hydrochloride salts Active 2039-12-18 AU2015274554B9 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462011315P 2014-06-12 2014-06-12
US62/011,315 2014-06-12
PCT/US2015/035316 WO2015191846A1 (en) 2014-06-12 2015-06-11 N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide hydrochloride salts

Publications (3)

Publication Number Publication Date
AU2015274554A1 AU2015274554A1 (en) 2016-11-24
AU2015274554B2 AU2015274554B2 (en) 2018-02-15
AU2015274554B9 true AU2015274554B9 (en) 2018-04-19

Family

ID=53674249

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015274554A Active 2039-12-18 AU2015274554B9 (en) 2014-06-12 2015-06-11 N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide hydrochloride salts

Country Status (36)

Country Link
US (5) US9469613B2 (https=)
EP (3) EP3154950B1 (https=)
JP (5) JP6600649B2 (https=)
KR (1) KR101928225B1 (https=)
CN (2) CN106458929A (https=)
AP (1) AP2016009551A0 (https=)
AR (1) AR100818A1 (https=)
AU (1) AU2015274554B9 (https=)
BR (1) BR112016028749A2 (https=)
CA (1) CA2951883C (https=)
CR (1) CR20160575A (https=)
CU (1) CU20160183A7 (https=)
CY (2) CY1123604T1 (https=)
DK (1) DK3154950T3 (https=)
EA (1) EA032639B1 (https=)
EC (1) ECSP16093323A (https=)
ES (1) ES2822773T3 (https=)
FI (1) FIC20240025I1 (https=)
FR (1) FR24C1030I2 (https=)
HR (1) HRP20201492T1 (https=)
HU (2) HUE051360T2 (https=)
IL (3) IL249038B (https=)
LT (2) LT3154950T (https=)
MA (1) MA40067A (https=)
MX (3) MX374541B (https=)
NL (1) NL301282I2 (https=)
NZ (1) NZ725966A (https=)
PH (1) PH12016502461A1 (https=)
PL (1) PL3154950T3 (https=)
PT (1) PT3154950T (https=)
RS (1) RS61065B1 (https=)
SG (2) SG11201610079VA (https=)
SI (1) SI3154950T1 (https=)
TW (3) TWI729644B (https=)
UY (1) UY36166A (https=)
WO (1) WO2015191846A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI729644B (zh) * 2014-06-12 2021-06-01 美商西爾拉癌症醫學公司 N-(氰基甲基)-4-(2-(4-𠰌啉基苯基胺基)嘧啶-4-基)苯甲醯胺
CN106316963B (zh) * 2015-06-26 2021-06-08 苏州泽璟生物制药股份有限公司 吗啡啉苯基氨基嘧啶化合物或其盐的多晶型物
CN106316964B (zh) * 2015-06-26 2019-06-25 苏州泽璟生物制药股份有限公司 苯基氨基嘧啶化合物或其盐的多晶型物
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
WO2018031579A1 (en) 2016-08-10 2018-02-15 Gilead Sciences, Inc. Momelotinib for treating of acvr1 -mediated diseases
KR102942294B1 (ko) * 2018-05-15 2026-03-23 장쑤 한서 파마슈티칼 그룹 캄파니 리미티드 소분자 이지에프알 억제제를 포함하는 약학 조성물 및 그의 제조 방법
KR20210047308A (ko) 2018-08-21 2021-04-29 시에라 온코로지, 인코퍼레이티드 골수섬유증을 치료하는 혈소판 수-불특정 방법
EP3923948A4 (en) * 2019-02-12 2022-11-16 Impact Biomedicines, Inc. CRYSTALLINE SHAPES OF A JAK2 INHIBITOR
CN114761013A (zh) 2019-09-27 2022-07-15 迪斯克医药公司 治疗骨髓纤维化和相关病症的方法
WO2021231798A1 (en) 2020-05-13 2021-11-18 Disc Medicine, Inc. Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
CN117794545A (zh) 2021-07-30 2024-03-29 葛兰素史密斯克莱有限责任公司 骨髓纤维化的治疗中的生物标志物和患者选择
EP4384181A2 (en) 2021-08-10 2024-06-19 GlaxoSmithKline LLC Momelotinib combination therapy
WO2023023473A1 (en) 2021-08-16 2023-02-23 Sierra Oncology, Inc. Methods of using momelotinib to treat chronic kidney disease
CN115957221B (zh) * 2021-10-09 2026-01-06 广东东阳光药业股份有限公司 抗纤维化组合物
WO2023152773A1 (en) * 2022-02-14 2023-08-17 Dr. Reddy's Institute Of Life Sciences Solid forms of momelotinib salts and improved processes for the preparation of momelotinib
CN119704552B (zh) * 2025-02-08 2025-06-13 泰州南洋塑料制品有限公司 一种电池槽注塑模具及边缘毛刺废料处理回收装置

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012071612A1 (en) * 2010-12-03 2012-06-07 Ym Biosciences Australia Pty Ltd Treatment of jak2-mediated conditions
US8486941B2 (en) * 2007-03-12 2013-07-16 Ym Biosciences Australia Pty Ltd Phenyl amino pyrimidine compounds and uses thereof

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3481932A (en) 1967-09-01 1969-12-02 Searle & Co 2-anilino-5-methyl-6-phenylpyrimidines and congeners
US4943593A (en) 1988-02-25 1990-07-24 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5182297A (en) 1988-02-25 1993-01-26 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5021456A (en) 1988-02-25 1991-06-04 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US4965288A (en) 1988-02-25 1990-10-23 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5059714A (en) 1988-02-25 1991-10-22 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5252608A (en) 1988-02-25 1993-10-12 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5120764A (en) 1988-11-01 1992-06-09 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US4997854A (en) 1989-08-25 1991-03-05 Trustees Of Boston University Anti-fibrotic agents and methods for inhibiting the activity of lysyl oxidase in-situ using adjacently positioned diamine analogue substrates
US5559714A (en) 1990-10-22 1996-09-24 Hallmark Cards, Incorporated Method and apparatus for display sequencing personalized social occasion products
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
US6376531B1 (en) * 1998-11-13 2002-04-23 Rupert Charles Bell Method of treatment using deuterium compounds
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
GB9924862D0 (en) 1999-10-20 1999-12-22 Celltech Therapeutics Ltd Chemical compounds
US7122544B2 (en) 2000-12-06 2006-10-17 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
US20040102455A1 (en) 2001-01-30 2004-05-27 Burns Christopher John Method of inhibiting kinases
EP1373257B9 (en) 2001-03-29 2008-10-15 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
FR2828206B1 (fr) 2001-08-03 2004-09-24 Centre Nat Rech Scient Utilisation d'inhibiteurs des lysyl oxydases pour la culture cellulaire et le genie tissulaire
US6433018B1 (en) 2001-08-31 2002-08-13 The Research Foundation Of State University Of New York Method for reducing hypertrophy and ischemia
RU2295329C2 (ru) 2001-09-12 2007-03-20 ВиРекс Медикал Корпорейшн Перекрывающее кровоток твердофазное средство с покрытием из иммобилизованного связывающего средства
DE60317198T2 (de) 2002-05-23 2008-12-04 Cytopia Research Pty. Ltd., Richmond Proteinkinaseinhibitoren
MXPA05001804A (es) 2002-08-14 2005-05-27 Vertex Pharma Inhibidores de proteinas cinasas y usos de los mismos.
JP2006512314A (ja) 2002-11-01 2006-04-13 バーテックス ファーマシューティカルズ インコーポレイテッド Ｊａｋインヒビターおよび他のプロテインキナーゼインヒビターとしての組成物の使用
EP1562938B1 (en) 2002-11-04 2007-08-29 Vertex Pharmaceuticals Incorporated Heteroaryl-pyrimidine derivatives as jak inhibitors
EP1560824A1 (en) 2002-11-05 2005-08-10 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of jak and other protein kinases
GB0317841D0 (en) 2003-07-30 2003-09-03 Cyclacel Ltd Compound
EP1648875A1 (en) 2003-07-30 2006-04-26 Cyclacel Limited 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
SI2612862T1 (sl) 2004-05-13 2017-04-26 Icos Corporation Kinazolini kot inhibitorji humane fosfatidilinozitol 3-kinaze delta
MX2007004488A (es) 2004-10-13 2007-09-11 Wyeth Corp Analogos de anilino-pirimidina n-bencenosulfonilo sustituidos.
US7593820B2 (en) 2005-05-12 2009-09-22 Cytopia Research Pty Ltd Crystal structure of human Janus Kinase 2 (JAK2) and uses thereof
KR20080110998A (ko) 2006-01-30 2008-12-22 엑셀리시스, 인코포레이티드 Ｊａｋ­２ 조절자로서 ４­아릴­２­아미노­피리미딘 또는 4­아릴­２­아미노알킬­피리미딘 및 이들을 포함하는 약제학적 조성물
BRPI0708347A2 (pt) 2006-02-28 2011-05-24 Cytopia Res Pty Ltd inibição jak2 como um tratamento da hipertensão arterial pulmonar
FR2911139A1 (fr) 2007-01-05 2008-07-11 Sanofi Aventis Sa Nouveaux derives de phenyl-(4-phenyl-pyrimidin-2-yl)amines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
AU2016200866B2 (en) 2007-03-12 2017-06-22 Glaxosmithkline Llc Phenyl amino pyrimidine compounds and uses thereof
AU2013201306B2 (en) 2007-03-12 2015-11-12 Glaxosmithkline Llc Phenyl Amino Pyrimidine Compounds and Uses Thereof
US8530480B2 (en) 2007-09-04 2013-09-10 The Scripps Research Institute Substituted pyrimidinyl-amines as protein kinase inhibitors
WO2009029998A1 (en) 2007-09-06 2009-03-12 Cytopia Research Pty Ltd Retrometabolic compounds
WO2009073575A2 (en) 2007-11-30 2009-06-11 Oregon Health & Science University Methods for treating induced cellular proliferative disorders
MX2011001426A (es) 2008-08-05 2011-03-21 Targegen Inc Metodos para tratar la talasemia.
UA102128C2 (en) 2008-12-05 2013-06-10 Х. Луннбек А/С Nalmefene hydrochloride dihydrate
US8450321B2 (en) 2008-12-08 2013-05-28 Gilead Connecticut, Inc. 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor
WO2010141946A1 (en) 2009-06-05 2010-12-09 Cell Targeting, Inc. Peptide-coated cell localization to diseased or damaged tissues and methods related thereto
JP5086385B2 (ja) * 2010-03-08 2012-11-28 日立オートモティブシステムズ株式会社 電動パワーステアリング制御装置
BR112012030711B1 (pt) 2010-05-31 2020-10-13 Ono Pharmaceutical Co. Ltd derivado de purinona
MD20130089A2 (ro) 2011-05-02 2014-05-31 Ym Biosciences Australia Pty Ltd Metodă de tratament al mielomului multiplu
US8809359B2 (en) 2012-06-29 2014-08-19 Ym Biosciences Australia Pty Ltd Phenyl amino pyrimidine bicyclic compounds and uses thereof
JPWO2014051056A1 (ja) * 2012-09-28 2016-08-22 東レ株式会社 グリシン誘導体の結晶及びその医薬用途
JP2016505015A (ja) 2013-01-09 2016-02-18 コンサート ファーマシューティカルズ インコーポレイテッド 重水素化モメロチニブ（ｍｏｍｅｌｏｔｉｎｉｂ）
CN103965114B (zh) 2013-01-28 2016-01-06 苏州泽璟生物制药有限公司 氘代的苯基氨基嘧啶化合物以及包含该化合物的药物组合物
TWI729644B (zh) * 2014-06-12 2021-06-01 美商西爾拉癌症醫學公司 N-(氰基甲基)-4-(2-(4-𠰌啉基苯基胺基)嘧啶-4-基)苯甲醯胺
CN106316964B (zh) * 2015-06-26 2019-06-25 苏州泽璟生物制药股份有限公司 苯基氨基嘧啶化合物或其盐的多晶型物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8486941B2 (en) * 2007-03-12 2013-07-16 Ym Biosciences Australia Pty Ltd Phenyl amino pyrimidine compounds and uses thereof
WO2012071612A1 (en) * 2010-12-03 2012-06-07 Ym Biosciences Australia Pty Ltd Treatment of jak2-mediated conditions

Also Published As

Publication number Publication date
IL276948A (en) 2020-10-29
HUE051360T2 (hu) 2021-03-01
FIC20240025I1 (fi) 2024-07-12
DK3154950T3 (da) 2020-09-14
EA201692356A1 (ru) 2017-07-31
AU2015274554B2 (en) 2018-02-15
JP2018184486A (ja) 2018-11-22
TWI681954B (zh) 2020-01-11
JP7198867B2 (ja) 2023-01-04
CN106458929A (zh) 2017-02-22
ES2822773T3 (es) 2021-05-04
NZ725966A (en) 2018-04-27
JP6840909B2 (ja) 2021-03-10
EP3154950A1 (en) 2017-04-19
TW202012378A (zh) 2020-04-01
FR24C1030I1 (fr) 2024-08-30
JP6600649B2 (ja) 2019-10-30
IL276948B (en) 2021-09-30
IL286442A (en) 2021-10-31
CR20160575A (es) 2017-01-20
AP2016009551A0 (en) 2016-11-30
MA40067A (fr) 2015-12-17
US20150361050A1 (en) 2015-12-17
TW202134236A (zh) 2021-09-16
MX2022015558A (es) 2023-01-30
TW201617323A (zh) 2016-05-16
CA2951883A1 (en) 2015-12-17
IL249038B (en) 2020-09-30
CY2024024I1 (el) 2025-03-28
USRE49445E1 (en) 2023-03-07
EP3907219A1 (en) 2021-11-10
CU20160183A7 (es) 2017-05-10
CA2951883C (en) 2020-05-05
USRE50497E1 (en) 2025-07-22
PL3154950T3 (pl) 2021-01-25
MX2016016294A (es) 2017-09-01
ECSP16093323A (es) 2017-01-31
HUS2400025I1 (hu) 2024-08-28
LTPA2024523I1 (https=) 2024-07-25
CY1123604T1 (el) 2022-03-24
NL301282I2 (nl) 2025-03-12
SG10201911925TA (en) 2020-01-30
CN110627728A (zh) 2019-12-31
BR112016028749A2 (pt) 2017-08-22
KR101928225B1 (ko) 2018-12-11
EA032639B1 (ru) 2019-06-28
JP2021107465A (ja) 2021-07-29
WO2015191846A1 (en) 2015-12-17
SI3154950T1 (sl) 2021-01-29
EP3719005A1 (en) 2020-10-07
EP3154950B1 (en) 2020-08-05
MX374541B (es) 2025-03-06
AU2015274554A1 (en) 2016-11-24
PH12016502461A1 (en) 2017-03-06
JP6883560B2 (ja) 2021-06-09
PT3154950T (pt) 2020-10-09
AR100818A1 (es) 2016-11-02
HRP20201492T1 (hr) 2021-01-08
USRE48285E1 (en) 2020-10-27
RS61065B1 (sr) 2020-12-31
FR24C1030I2 (fr) 2025-06-13
IL249038A0 (en) 2017-01-31
JP7550205B2 (ja) 2024-09-12
TWI729644B (zh) 2021-06-01
LT3154950T (lt) 2020-11-25
JP2017517535A (ja) 2017-06-29
CY2024024I2 (el) 2025-03-28
KR20170015496A (ko) 2017-02-08
JP2020059759A (ja) 2020-04-16
US20160347719A1 (en) 2016-12-01
UY36166A (es) 2016-01-29
MX2019009564A (es) 2019-10-02
SG11201610079VA (en) 2016-12-29
US9809559B2 (en) 2017-11-07
US9469613B2 (en) 2016-10-18
JP2023021454A (ja) 2023-02-10

Similar Documents

Publication Publication Date Title
USRE50497E1 (en) (N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide
US10479770B2 (en) Phosphatidylinositol 3-kinase inhibitors
US9499523B2 (en) Phosphatidylinositol 3-kinase inhibitors
TW201609105A (zh) 治療骨髓增生失調之療法
EP3331531A1 (en) Combination therapies for treating cancers
HK40063342A (en) N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide hydrochloride salts
HK1236527A1 (en) N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide hydrochloride salts
HK1236527B (en) N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide hydrochloride salts
HK1231079A1 (en) N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide hydrochloride salts

Legal Events

Date Code Title Description
SREP Specification republished
SREP Specification republished
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: SIERRA ONCOLOGY, INC.

Free format text: FORMER OWNER(S): GILEAD SCIENCES, INC.

PC Assignment registered

Owner name: GLAXOSMITHKLINE LLC

Free format text: FORMER OWNER(S): SIERRA ONCOLOGY, INC.

NC Extension of term for standard patent requested (sect. 70)

Free format text: PRODUCT NAME: OMJJARA MOMELOTINIB

Filing date: 20241218

NDA Extension of term for standard patent accepted (sect.70)

Free format text: PRODUCT NAME: OMJJARA MOMELOTINIB

Filing date: 20241218

NDB Extension of term for standard patent granted (sect.76)

Free format text: PRODUCT NAME: OMJJARA MOMELOTINIB

Filing date: 20241218

Extension date: 20391218